Newsletter Tool

PM Tracker

Today’s Big News

Aug 27, 2024

FDA clears its first automated insulin pump for type 2 diabetes, with Insulet’s Omnipod 5

After guiding Endo through bankruptcy, CEO Coleman exits suddenly

Navigator charts course for newly acquired autoimmune pipeline with $100M series A

Pfizer finalizes DTC virtual health platform for streamlined access to vaccines, tests and treatments

Eli Lilly rolls out direct patient access to weight loss star Zepbound—at a deep discount

After J&J-partnered epilepsy drug flop, Addex gets good news: Indivior has picked up its addiction asset

Duality plans Hong Kong IPO to fund trials of BioNTech-partnered ADCs and beyond

Featured

FDA clears its first automated insulin pump for Type 2 diabetes, with Insulet's Omnipod 5

By Conor Hale

The clearance opens the door for Insulet's Omnipod 5 wearable delivery system to be used by as many as 6 million people in the U.S. with Type 2 diabetes who require daily insulin.

After guiding Endo through bankruptcy, CEO Blaise Coleman exits suddenly

By Kevin Dunleavy

Four months after emerging from bankruptcy, Endo Pharmaceuticals is in transition again with the sudden departure of CEO Blaise Coleman. Without providing a reason, the Dublin-based company revealed that Coleman’s eventful four-year tenure will end on Thursday.

Navigator charts course for newly acquired autoimmune pipeline with $100M series A

By James Waldron

Navigator Medicines has equipped itself with $100 million in series A funds as the young biotech charts a course for its newly acquired autoimmune drugs.

Pfizer finalizes DTC virtual health platform for streamlined access to vaccines, tests and treatments

By Andrea Park

Just a few months after confirming that it was in the process of developing an online service to cut out middlemen and work directly with patients to help them access vaccines, diagnostic tests and medications, Pfizer has made good on its word.

Eli Lilly rolls out direct patient access to weight loss star Zepbound—at a deep discount

By Zoey Becker

Eli Lilly is offering its popular weight-loss drug Zepbound directly to consumers at a discount through its own online pharmacy. The company hopes the move could expand access while addressing other issues such as high prices and off-label cosmetic usage.

After J&J-partnered epilepsy drug flop, Addex gets good news: Indivior has picked up its addiction asset

By Gabrielle Masson

Indivior is picking up a small molecule allosteric modulator designed to treat substance use disorder from Addex Therapeutics, providing the latter the chance to make up to $300 million in biobucks, plus royalties.

Duality plans Hong Kong IPO to fund trials of BioNTech-partnered ADCs and beyond

By Nick Paul Taylor

China’s Duality Biotherapeutics has filed paperwork for a Hong Kong IPO, seeking an undisclosed sum to power a broad pipeline of antibody-drug conjugates toward approval. The filing extends the recent flurry of IPO activity beyond the U.S. and into Asia.

Boston Scientific nets earlier-than-expected TAVR approval in Europe

By Conor Hale

The company’s Acurate Prime system is built on the same platform as its predecessor, the Acurate Neo2, which launched on the continent in late 2020.

YolTech sells China rights to cholesterol gene editing therapy to Salubris for $29M

By James Waldron

Four months after Chinese gene editing company YolTech Therapeutics took its cholesterol disease-focused candidate into the clinic, Salubris Pharmaceuticals has secured the local rights to the drug for 205 million Chinese yuan ($28.7 million).

Cleveland Diagnostics re-ups prostate-specific antigen test push in ‘A PSA on PSA’

By Andrea Park

In tandem with September’s Prostate Cancer Awareness Month, Cleveland Diagnostics is kicking off a campaign to boost awareness of and education around screening tests for the disease.

Fierce podcasts

Don’t miss an episode

'The Top Line': What Chevron’s overturn means for biopharma

This week on "The Top Line," we look at the potential effects of the Chevron overturn on the biopharma industry.

'The Top Line': The TROP2 race for supremacy

‘Podnosis’: How incentives engage and keep patients healthy

Resources

Whitepaper

Epilepsy Clinical Trials

Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner.

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs.